ACN vs ARM

Accenture (ACN) exhibits mixed fundamental health, with a Piotroski F-Score of 4/9 indicating a borderline stable financial position, and no Altman Z-Score available to assess distress risk. The stock trades at a premium to its Graham Number ($116.86) and intrinsic value estimate ($84.7), suggesting valuation is driven by growth expectations rather than conservative safety. Despite strong profitability metrics—ROE of 25.02% and gross margin of 31.97%—earnings growth has turned negative (-1.60% YoY), and recent price performance reflects significant underperformance over 1Y (-39.2%) and 5Y (-20.8%). Analysts remain optimistic with a buy recommendation and a target price of $268.51, but insider activity is neutral, and technical trends are bearish.

ARM exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust operational efficiency and profitability, though the absence of an Altman Z-Score prevents definitive distress risk assessment. The stock trades at a premium valuation (P/E 154.33, Forward P/E 54.10) relative to its intrinsic value estimates ($5.25 intrinsic, $11.13 Graham), suggesting high growth expectations are priced in. Despite a recent earnings decline (YoY -12.3%), revenue growth remains strong at 26.3%, supported by consistent earnings surprises in the last four quarters. However, the lack of dividend, weak technical trend, and elevated valuation pose near-term risks. Analysts remain bullish with a buy consensus and target price above current levels.